Home › Trial NCT00286169
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
- Trial IDNCT00286169
- StatusTerminated
- PhasePhase 3
- Study typeInterventional
- SponsorSumitomo Pharma Co., Ltd.
- Enrollment130
- Start date2006-04
- ConditionsSmall-cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.